CV Lattes
ResearcherID
ORCID
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Instituto Nacional de Farmacologia (INFAR) (Institutional affiliation from the last research proposal) Birthplace: Brazil
graduate at Biological Science from F.F.C.L. Barão de Mauá, Ribeirão Preto (1975), master at Pharmacology from Universidade Federal de São Paulo (1978) and PhD at Pharmacology from Universidade Federal de São Paulo (1984). He is currently associate professor at Universidade Federal de São Paulo. Has experience in Pharmacology, focusing on Pharmacology Molecular Biochemistry, acting on the following subjects: expression, intracellular signaling and function of estrogen receptor in the male reproductive tract. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| TITULO |
| Articles published in other media outlets (0 total): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Prostate cancer initially responds well to androgen-deprivation therapies, but the majority of tumors evolve from an androgen-sensitive to an androgen-independent form of the disease, also known as castration-resistant prostate cancer (CRPC), which presents a poor prognosis and no effective therapy. Recent studies from our laboratory have shown the expression and the extranuclear localiza…
Prostate cancer initially responds well to androgen-deprivation therapies, but the majority of tumors evolve from an androgen-sensitive to an androgen-independent form of the disease, also known to castration-resistant prostate cancer (CRPC). The molecular mechanisms involved are still not well understood. The androgen-independent prostate cancer cell lines PC-3, derived from a bone metas…
Testicular cancer has the one of the highest cure rates among all cancer. However, it has been observed, in addition to male infertility, the resistance to treatment in 30% of the patients with metastatic non-seminoma testicular cancer. There are many genes and signaling pathways associated with testicular cancer. Estrogens, their receptors (ESR1 and ESR2) and signaling pathways may play …
(Only some records are available in English at this moment)
Dynamic changes in the expression of estrogen receptors have been shown with the progression of prostate cancer. Studies have shown that in the early stages of prostatic carcinoma, the genes encoding the ESR1 and ESR2 estrogen receptors are silenced, occurring low expression of these receptors in tumors confined on prostate. However, ESR1 reappears with cancer progression and, in the meta…
Direct and indirect effects of estrogen have been shown in the development and homeostasis of the prostate tissue and in the etiology of prostatic diseases. However, the role of this hormone in the development of castration-resistant prostate cancer (CRPC) is not well established. Estrogen can act via the classical receptors ESR1 (ERalpha) and ESR2 (ERbeta), located predominantly in epith…
Testicular germ cell tumors type II are classified into two main categories: seminoma and nonseminoma (including embryonal carcinoma), both derived from common precursor cell type called carcinoma in situ. The dormancy period of these tumors until puberty suggests a hormone-dependent mechanism for development or progression of the tumor. Estrogen could play a role in this process. In semi…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing research grants |
| 19 / 9 | Completed research grants |
| 17 / 7 | Completed scholarships in Brazil |
| 38 / 18 | All research grants and scholarships |
| Associated processes | |